Sunshine Biopharma Inc. announced that it has acquired all of the right, title, and interest in and to U.S. Patent Number 8,236,935 for the Company’s Adva-27a anticancer compound.
The Patent Purchase Agreement executed today provides Sunshine with ownership of the patent, which includes all rights to this intellectual property within the United States. Prior, Sunshine had been licensing the right to use this patent from Advanomics Corporation, a privately held Canadian company that currently owns approximately 23% of Sunshine’s issued and outstanding Common Stock. The executed Patent Purchase Agreement also terminates the License Agreement between Sunshine and Advanomics and eliminates all obligations of Sunshine thereunder.
